Literature DB >> 27866773

Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.

Dan Zheng1, Shaoheng Chen1, Di Qu2, Jianjun Chen3, Fuyan Wang4, Ran Zhang5, Ze Chen6.   

Abstract

The long alpha-helix (LAH) region located in influenza virus hemagglutinin (HA) shows conservation among different influenza A strains, which could be used as a candidate target of influenza vaccines. Moreover, the hepatitis B virus core protein (HBc) is a carrier for heterologous epitopes in eliciting effective immune responses. We inserted the LAH region of H7N9 influenza virus into the HBc and prepared the LAH-HBc protein, which were capable of self-assembly into virus-like particles (VLP), by using E. coli expression system. Intranasal immunization of the LAH-HBc VLP in combination with chitosan adjuvant or CTB∗ adjuvant in mice could induce both humoral and cellular immune responses effectively and provide complete protection against lethal challenge of homologous H7N9 virus or heterologous H3N2 virus, as well as partial protection against lethal challenge of heterologous H1N1 virus. These results provide a proof of concept for LAH-HBc VLP vaccine that would be fast and easy to be produced and might be an ideal candidate as a rapid-response tool against a future influenza pandemic. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; H7N9; Influenza; LAH-HBc VLP

Mesh:

Substances:

Year:  2016        PMID: 27866773     DOI: 10.1016/j.vaccine.2016.11.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates.

Authors:  Andris Kazaks; I-Na Lu; Sophie Farinelle; Alex Ramirez; Vincenzo Crescente; Benjamin Blaha; Olotu Ogonah; Tarit Mukhopadhyay; Mapi Perez de Obanos; Alejandro Krimer; Inara Akopjana; Janis Bogans; Velta Ose; Anna Kirsteina; Tatjana Kazaka; Nicola J Stonehouse; David J Rowlands; Claude P Muller; Kaspars Tars; William M Rosenberg
Journal:  BMC Biotechnol       Date:  2017-11-10       Impact factor: 2.563

Review 2.  Engineering self-assembled materials to study and direct immune function.

Authors:  Lisa H Tostanoski; Christopher M Jewell
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

3.  An Influenza A Vaccine Based on the Extracellular Domain of Matrix 2 Protein Protects BALB/C Mice Against H1N1 and H3N2.

Authors:  Hui Kian Ong; Chean Yeah Yong; Wen Siang Tan; Swee Keong Yeap; Abdul Rahman Omar; Mariatulqabtiah Abdul Razak; Kok Lian Ho
Journal:  Vaccines (Basel)       Date:  2019-08-19

4.  Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant.

Authors:  Jian Luo; Xu-Ping Liu; Fei-Fei Xiong; Fei-Xia Gao; Ying-Lei Yi; Min Zhang; Ze Chen; Wen-Song Tan
Journal:  Front Immunol       Date:  2019-09-27       Impact factor: 7.561

Review 5.  Hepatitis B core-based virus-like particles: A platform for vaccine development in plants.

Authors:  Maryam Moradi Vahdat; Farshad Hemmati; Abozar Ghorbani; Daria Rutkowska; Alireza Afsharifar; Mohammad Hadi Eskandari; Nahid Rezaei; Ali Niazi
Journal:  Biotechnol Rep (Amst)       Date:  2021-02-28

6.  Designing a multi-epitope vaccine to provoke the robust immune response against influenza A H7N9.

Authors:  Hossein Tarrahimofrad; Somayyeh Rahimnahal; Javad Zamani; Ehsan Jahangirian; Saeed Aminzadeh
Journal:  Sci Rep       Date:  2021-12-29       Impact factor: 4.379

Review 7.  Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.

Authors:  Farshad Hemmati; Mohsen Hemmati-Dinarvand; Marziye Karimzade; Daria Rutkowska; Mohammad Hadi Eskandari; Sayyad Khanizadeh; Alireza Afsharifar
Journal:  Biotechnol Lett       Date:  2021-11-27       Impact factor: 2.716

8.  Applying Unique Molecular Identifiers in Next Generation Sequencing Reveals a Constrained Viral Quasispecies Evolution under Cross-Reactive Antibody Pressure Targeting Long Alpha Helix of Hemagglutinin.

Authors:  Nastasja C Hauck; Josiane Kirpach; Christina Kiefer; Sophie Farinelle; Sophie Maucourant; Stephen A Morris; William Rosenberg; Feng Q He; Claude P Muller; I-Na Lu
Journal:  Viruses       Date:  2018-03-25       Impact factor: 5.048

Review 9.  Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.

Authors:  Peter Pushko; Irina Tretyakova
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

Review 10.  Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.

Authors:  Cynthia Calzas; Christophe Chevalier
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.